Open Scanner

Specify a stock or a cryptocurrency in the search bar to get a summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

CytomX Therapeutics Inc

CTMX
Current price
1.47 USD +0.02 USD (+1.38%)
Last closed 1.46 USD
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 94 454 344 USD
Yield for 12 month -5.16 %
Week
Month
Year
CTMX
21.11.2021 - 28.11.2021

CytomX Therapeutics, Inc., a clinical-stage, oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company's pipeline comprises therapeutic candidates across multiple treatment modalities, including antibody-drug conjugates (ADCs), T-cell engaging bispecific antibodies, and immune modulators, such as cytokines and checkpoint inhibitors. CX-2029 is an investigational conditional ADC directed toward CD71. Its clinical pipeline also includes cancer immunotherapeutic candidates against validated targets, such as the CTLA-4-targeting Probody therapeutic BMS-986288, partnered with Bristol Myers Squibb, as well as CX-904, a T-cell-engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells, which is partnered with Amgen. In addition, it has a preclinical portfolio of wholly owned assets, including CX-801, an interferon alpha-2b Probody cytokine that has potential applicability in immuno-oncology sensitive, as well as insensitive (cold) tumors and CX-2051, an ADC directed toward EpCAM with potential applicability across multiple EpCAM-expressing epithelial cancers. The company has strategic collaborations with various leaders in oncology, including Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna. The company was founded in 2008 and is headquartered in South San Francisco, California. Address: 151 Oyster Point Boulevard, South San Francisco, CA, United States, 94080

Analytics

WallStreet Target Price

2.61 USD

P/E ratio

Dividend Yield

Current Year

+53 163 000 USD

Last Year

+69 573 000 USD

Current Quarter

+26 384 000 USD

Last Quarter

+24 724 000 USD

Current Year

+53 163 000 USD

Last Year

+69 573 000 USD

Current Quarter

+26 384 000 USD

Last Quarter

+24 724 000 USD

Key Figures CTMX

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA -5 389 000 USD
Operating Margin TTM 11.84 %
PE Ratio
Return On Assets TTM -2.15 %
PEG Ratio -1.8
Return On Equity TTM -5475.03 %
Wall Street Target Price 2.61 USD
Revenue TTM 94 730 000 USD
Book Value -0.77 USD
Revenue Per Share TTM 1.35 USD
Dividend Share
Quarterly Revenue Growth YOY 136.7 %
Dividend Yield
Gross Profit TTM 53 163 000 USD
Earnings Share -0.15 USD
Diluted Eps TTM -0.15 USD
Most Recent Quarter III 2023
Quarterly Earnings Growth YOY
Profit Margin -10.75 %

Dividend Analytics CTMX

Dividend growth over 5 years

Continuous growth

Payout Ratio 5 years average

Dividend History CTMX

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
Ex Dividend Date
Forward Annual Dividend Yield
Last Split Factor
Payout Ratio
Last Split Date
Dividend Date

Stock Valuation CTMX

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE
Enterprise Value Revenue 0.7429
Price Sales TTM 0.9971
Enterprise Value EBITDA 6.4635
Price Book MRQ 5.0363

Financials CTMX

1 year
3 years
5 years
10 years
Results 2019 Dynamics

Technical indicators CTMX

For 52 weeks

1.04 USD 3.02 USD
50 Day MA 1.26 USD
Shares Short Prior Month 1 258 790
200 Day MA 1.59 USD
Short Ratio 6.05
Shares Short 1 332 844
Short Percent 2 %